(BIIB) Biogen - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09062X1037
Stock:
Total Rating 56
Risk 85
Buy Signal -0.34
| Risk 5d forecast | |
|---|---|
| Volatility | 29.8% |
| Relative Tail Risk | -5.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 20.97 |
| Character TTM | |
|---|---|
| Beta | 0.642 |
| Beta Downside | 0.731 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.35% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Description: BIIB Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.70 > 1.0 |
| NWC/Revenue: 57.33% < 20% (prev 19.93%; Δ 37.41% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.20b > Net Income 1.29b |
| Net Debt (3.94b) to EBITDA (3.10b): 1.27 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (146.7m) vs 12m ago 0.41% < -2% |
| Gross Margin: 70.47% > 18% (prev 0.72%; Δ 6975 % > 0.5%) |
| Asset Turnover: 34.13% > 50% (prev 34.50%; Δ -0.37% > 0%) |
| Interest Coverage Ratio: 8.09 > 6 (EBITDA TTM 3.10b / Interest Expense TTM 267.5m) |
Altman Z'' 5.95
| A: 0.19 (Total Current Assets 8.97b - Total Current Liabilities 3.35b) / Total Assets 29.44b |
| B: 0.70 (Retained Earnings 20.55b / Total Assets 29.44b) |
| C: 0.08 (EBIT TTM 2.17b / Avg Total Assets 28.74b) |
| D: 1.82 (Book Value of Equity 20.37b / Total Liabilities 11.18b) |
| Altman-Z'' Score: 5.95 = AAA |
Beneish M -3.06
| DSRI: 0.99 (Receivables 1.87b/1.87b, Revenue 9.81b/9.68b) |
| GMI: 1.03 (GM 70.47% / 72.34%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.61) |
| SGI: 1.01 (Revenue 9.81b / 9.68b) |
| TATA: -0.03 (NI 1.29b - CFO 2.20b) / TA 29.44b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of BIIB shares?
As of March 04, 2026, the stock is trading at USD 188.05 with a total of 671,519 shares traded.
Over the past week, the price has changed by -4.22%, over one month by +5.00%, over three months by +4.37% and over the past year by +32.70%.
Over the past week, the price has changed by -4.22%, over one month by +5.00%, over three months by +4.37% and over the past year by +32.70%.
Is BIIB a buy, sell or hold?
Biogen has received a consensus analysts rating of 3.81.
Therefore, it is recommended to buy BIIB.
- StrongBuy: 13
- Buy: 4
- Hold: 20
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BIIB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 205.7 | 9.4% |
| Analysts Target Price | 205.7 | 9.4% |
BIIB Fundamental Data Overview February 28, 2026
P/E Trailing = 21.3659
P/E Forward = 9.6899
P/S = 2.7899
P/B = 1.2908
P/EG = 6.2424
Revenue TTM = 9.81b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 3.10b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 80.4m USD (from shortTermDebt, last quarter)
Debt = 6.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.94b USD (from netDebt column, last quarter)
Enterprise Value = 30.73b USD (27.59b + Debt 6.95b - CCE 3.82b)
Interest Coverage Ratio = 8.09 (Ebit TTM 2.17b / Interest Expense TTM 267.5m)
EV/FCF = 14.37x (Enterprise Value 30.73b / FCF TTM 2.14b)
FCF Yield = 6.96% (FCF TTM 2.14b / Enterprise Value 30.73b)
FCF Margin = 21.80% (FCF TTM 2.14b / Revenue TTM 9.81b)
Net Margin = 13.18% (Net Income TTM 1.29b / Revenue TTM 9.81b)
Gross Margin = 70.47% ((Revenue TTM 9.81b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 78.23% (prev 64.29%)
Tobins Q-Ratio = 1.04 (Enterprise Value 30.73b / Total Assets 29.44b)
Interest Expense / Debt = 0.97% (Interest Expense 67.5m / Debt 6.95b)
Taxrate = 7.71% (108.1m / 1.40b)
NOPAT = 2.00b (EBIT 2.17b * (1 - 7.71%))
Current Ratio = 2.68 (Total Current Assets 8.97b / Total Current Liabilities 3.35b)
Debt / Equity = 0.38 (Debt 6.95b / totalStockholderEquity, last quarter 18.26b)
Debt / EBITDA = 1.27 (Net Debt 3.94b / EBITDA 3.10b)
Debt / FCF = 1.84 (Net Debt 3.94b / FCF TTM 2.14b)
Total Stockholder Equity = 17.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 1.29b / Total Assets 29.44b)
RoE = 7.28% (Net Income TTM 1.29b / Total Stockholder Equity 17.77b)
RoCE = 9.00% (EBIT 2.17b / Capital Employed (Equity 17.77b + L.T.Debt 6.29b))
RoIC = 8.31% (NOPAT 2.00b / Invested Capital 24.06b)
WACC = 6.79% (E(27.59b)/V(34.54b) * Re(8.28%) + D(6.95b)/V(34.54b) * Rd(0.97%) * (1-Tc(0.08)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 84.28% ; FCFF base≈2.29b ; Y1≈2.63b ; Y5≈3.69b
[DCF] Fair Price = 540.6 (EV 83.27b - Net Debt 3.94b = Equity 79.33b / Shares 146.8m; r=6.79% [WACC]; 5y FCF grow 17.62% → 2.90% )
EPS Correlation: -40.56 | EPS CAGR: -18.97% | SUE: 0.63 | # QB: 0
Revenue Correlation: -39.75 | Revenue CAGR: -2.76% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.32 | Chg7d=-0.002 | Chg30d=+0.370 | Revisions Net=+6 | Analysts=23
EPS current Year (2026-12-31): EPS=15.69 | Chg7d=+0.021 | Chg30d=+0.610 | Revisions Net=+9 | Growth EPS=+2.7% | Growth Revenue=-4.8%
EPS next Year (2027-12-31): EPS=16.24 | Chg7d=-0.076 | Chg30d=+0.395 | Revisions Net=+6 | Growth EPS=+3.5% | Growth Revenue=-0.7%
[Analyst] Revisions Ratio: +0.43 (10 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 8.3% - Earnings Yield 4.7%)
[Growth] Growth Spread = -13.1% (Analyst -9.5% - Implied 3.6%)
P/E Forward = 9.6899
P/S = 2.7899
P/B = 1.2908
P/EG = 6.2424
Revenue TTM = 9.81b USD
EBIT TTM = 2.17b USD
EBITDA TTM = 3.10b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 80.4m USD (from shortTermDebt, last quarter)
Debt = 6.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.94b USD (from netDebt column, last quarter)
Enterprise Value = 30.73b USD (27.59b + Debt 6.95b - CCE 3.82b)
Interest Coverage Ratio = 8.09 (Ebit TTM 2.17b / Interest Expense TTM 267.5m)
EV/FCF = 14.37x (Enterprise Value 30.73b / FCF TTM 2.14b)
FCF Yield = 6.96% (FCF TTM 2.14b / Enterprise Value 30.73b)
FCF Margin = 21.80% (FCF TTM 2.14b / Revenue TTM 9.81b)
Net Margin = 13.18% (Net Income TTM 1.29b / Revenue TTM 9.81b)
Gross Margin = 70.47% ((Revenue TTM 9.81b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 78.23% (prev 64.29%)
Tobins Q-Ratio = 1.04 (Enterprise Value 30.73b / Total Assets 29.44b)
Interest Expense / Debt = 0.97% (Interest Expense 67.5m / Debt 6.95b)
Taxrate = 7.71% (108.1m / 1.40b)
NOPAT = 2.00b (EBIT 2.17b * (1 - 7.71%))
Current Ratio = 2.68 (Total Current Assets 8.97b / Total Current Liabilities 3.35b)
Debt / Equity = 0.38 (Debt 6.95b / totalStockholderEquity, last quarter 18.26b)
Debt / EBITDA = 1.27 (Net Debt 3.94b / EBITDA 3.10b)
Debt / FCF = 1.84 (Net Debt 3.94b / FCF TTM 2.14b)
Total Stockholder Equity = 17.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.50% (Net Income 1.29b / Total Assets 29.44b)
RoE = 7.28% (Net Income TTM 1.29b / Total Stockholder Equity 17.77b)
RoCE = 9.00% (EBIT 2.17b / Capital Employed (Equity 17.77b + L.T.Debt 6.29b))
RoIC = 8.31% (NOPAT 2.00b / Invested Capital 24.06b)
WACC = 6.79% (E(27.59b)/V(34.54b) * Re(8.28%) + D(6.95b)/V(34.54b) * Rd(0.97%) * (1-Tc(0.08)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.34%
[DCF] Terminal Value 84.28% ; FCFF base≈2.29b ; Y1≈2.63b ; Y5≈3.69b
[DCF] Fair Price = 540.6 (EV 83.27b - Net Debt 3.94b = Equity 79.33b / Shares 146.8m; r=6.79% [WACC]; 5y FCF grow 17.62% → 2.90% )
EPS Correlation: -40.56 | EPS CAGR: -18.97% | SUE: 0.63 | # QB: 0
Revenue Correlation: -39.75 | Revenue CAGR: -2.76% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.32 | Chg7d=-0.002 | Chg30d=+0.370 | Revisions Net=+6 | Analysts=23
EPS current Year (2026-12-31): EPS=15.69 | Chg7d=+0.021 | Chg30d=+0.610 | Revisions Net=+9 | Growth EPS=+2.7% | Growth Revenue=-4.8%
EPS next Year (2027-12-31): EPS=16.24 | Chg7d=-0.076 | Chg30d=+0.395 | Revisions Net=+6 | Growth EPS=+3.5% | Growth Revenue=-0.7%
[Analyst] Revisions Ratio: +0.43 (10 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 8.3% - Earnings Yield 4.7%)
[Growth] Growth Spread = -13.1% (Analyst -9.5% - Implied 3.6%)